DCPH
Deciphera Pharmaceuticals, Inc.
Set alert
25.59 0.00 0.00%
25.56 Day range 25.61
52-week range unavailable
- Open
- 25.56
- Prev close
- 25.59
- Mkt cap
- 2.21B
- Vol
- 1.57M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 25.56
- High
- 25.61
- Forward P/E
- -15.23
- Beta
- 0.18
- Short ratio
- 1.05
- Inst. own
- 72.03%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 10, 2024
- 50-d avg
- 21.67
- 200-d avg
- 15.94
- 1y target
- 27.52
Key statistics
- Market cap
- 2.21B
- Enterprise value
- 1.97B
- Trailing P/E
- 0.00
- Forward P/E
- -15.23
- PEG ratio
- -0.62
- Price / sales
- 12.65
- Price / book
- 6.65
- EPS (TTM)
- -2.21
- Beta
- 0.18
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -108.86%
- Revenue (TTM)
- 174.91M
- Revenue growth
- 34.50%
- Free cash flow
- -80.09M
- Total cash
- 272.53M
- Total debt
- 25.02M
- Return on equity
- -50.37%
- Shares outstanding
- 86.48M
- Short % of float
- 6.33%
- 50-day average
- 21.67
- 200-day average
- 15.94
Analyst view
Consensus: hold
Hold
Price target (mean) 27.52 +7.5% upside
Now 25.59
- Target (low)
- 25.60
- Target (mean)
- 27.52
- Target (high)
- 30.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
May 10, 2024
Expected May 10, 2024. Consensus EPS estimate -0.51.
Financials — quick view
DCPH Revenue — quarterly 45.00M
DCPH Net income — quarterly -45.08M
DCPH EPS — quarterly -0.52
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 10, 2024 | Mar 1, 2024 | -0.55 | — | — | — |
| Feb 6, 2024 | Dec 1, 2023 | -0.58 | — | — | — |
| Oct 30, 2023 | Sep 1, 2023 | -0.60 | — | — | — |
| Aug 9, 2023 | Jun 1, 2023 | -0.62 | — | — | — |
| May 3, 2023 | Mar 1, 2023 | -0.60 | — | — | — |
| Feb 7, 2023 | Dec 1, 2022 | -0.57 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 9, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 9, 2023 | Stifel | up | Hold | Buy |
| Jun 4, 2023 | JMP Securities | reit | — | Market Outperform |
| May 3, 2023 | JMP Securities | reit | — | Market Outperform |
| Mar 14, 2023 | JMP Securities | reit | — | Market Outperform |
| Feb 7, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. As of June 11, 2024, Deciphera Pharmaceuticals, Inc. operates as a subsidiary of Ono Pharmaceutical Co., Ltd.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- deciphera.com
News
- Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
- Deciphera Announces the Opening of a New Office in Zug, Switzerland
- Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025
- Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025
- Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
- Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
- U.S. FDA Grants Full Approval of Deciphera's ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
- European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
- Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
- Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why
Your note
Sign in to keep a note on DCPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRIGHTSTARS ASSOCIATES, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 21, 2024 | 23,107,800 |
| DHANAK DASHYANT | Officer | Stock Award(Grant) | Jun 10, 2024 | 0 |
| FLYNN DANIEL LEE | Officer | Sale | Jun 15, 2023 | 378,613 |
| FRIEDMAN FRANKLIN STUART | Director | Purchase | Jun 7, 2023 | 10,000 |
| HOERTER STEVEN L | Chief Executive Officer | Stock Award(Grant) | Jun 10, 2024 | 0 |
| KELLY THOMAS P. | Chief Financial Officer | Sale | Jun 15, 2023 | 57,140 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 8.51% | 6,707,026 | 94.43M | Jun 29, 2023 |
| Blackrock Inc. | 6.94% | 5,467,999 | 76.99M | Jun 29, 2023 |
| Redmile Group, LLC | 6.19% | 4,878,566 | 68.69M | Jun 29, 2023 |
| Armistice Capital, LLC | 5.79% | 4,560,000 | 64.20M | Jun 29, 2023 |
| Vanguard Group Inc | 5.57% | 4,392,270 | 61.84M | Jun 29, 2023 |
| Braidwell LP | 4.63% | 3,646,419 | 51.34M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.47% | 1,947,744 | 27.35M | Aug 30, 2023 |
| Vanguard Total Stock Market Index Fund | 2.23% | 1,760,798 | 24.79M | Jun 29, 2023 |
| iShares Russell 2000 ETF | 1.52% | 1,194,319 | 16.77M | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 1.02% | 801,229 | 11.28M | Jun 29, 2023 |
| Vanguard Strategic Equity Fund | 0.95% | 747,816 | 10.53M | Jun 29, 2023 |
| College Retirement Equities Fund-Stock Account | 0.83% | 653,297 | 9.20M | Jun 29, 2023 |